billHR7994•Event Thursday, June 25, 2026Analyzed

HERO Act

Bullish

Summary

The HERO Act (HR 7994) would establish a grant program for schools to purchase opioid overdose reversal drugs, boosting demand for naloxone manufacturers like Emergent BioSolutions. The bill has been forwarded by subcommittee to full committee, indicating some momentum, but no specific funding amount is authorized.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.The HERO Act aims to increase naloxone availability in schools through a grant program.
  • 2.Emergent BioSolutions ($EBS) is the primary manufacturer of Narcan, the most widely used opioid overdose reversal drug.
  • 3.The bill is still in committee; no funding amount is specified, so the impact is modest and contingent on future appropriations.

Market Implications

The bill's progress is a positive signal for the opioid reversal drug market, particularly for $EBS. However, without a specific authorized funding level, the near-term revenue impact is uncertain. The stock may see modest upward pressure on legislative momentum, but significant gains require passage and appropriation.

Full Analysis

The HERO Act, introduced by Rep. Ruiz, would create a competitive grant program through HHS to help schools purchase FDA-approved opioid overdose reversal drugs (primarily naloxone) and develop educational programming. The bill was forwarded by the Subcommittee on Health to the full Committee on Energy and Commerce on June 25, 2026, via voice vote. It is still in the early legislative stages and has not yet been voted on by the full House or Senate. The bill does not specify an authorized funding amount, meaning actual appropriations would be determined separately. The primary beneficiaries are naloxone manufacturers, with Emergent BioSolutions ($EBS) being the leading producer of Narcan. The bill also requires schools receiving federal funds to report any distribution of opioid reversal drugs, which marginally increases administrative burden on schools but does not have direct market impact. The legislative path forward includes consideration by the full Energy and Commerce Committee, then the House floor, and potentially Senate action. Given the bipartisan nature of opioid-related legislation, the bill has moderate chances of eventual passage, but the lack of a specific dollar amount limits near-term revenue visibility.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$EBS▲ Bullish
Est. $5.0M – $20.0M revenue impact
①

What the bill does

Grant program authorized for schools to purchase opioid overdose reversal drugs; reporting requirement for distributions.

②

Who must act

Schools and local educational agencies receiving federal funds.

③

What happens

Increased procurement of naloxone and other opioid reversal drugs by schools, boosting demand.

④

Stock impact

Emergent BioSolutions manufactures Narcan (naloxone nasal spray), the leading brand. The grant program could increase school purchases, contributing to revenue growth in its naloxone product line.

Key Legislators

Rep. Ruiz, Raul [D-CA-25]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderSep 18, 2026

Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program

This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.

proclamationSep 8, 2026

Accelerating Access To Veterans' Benefits And Employment Opportunities

This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.

Exec OrderAug 10, 2026

Delivering Gold Standard Childhood Vaccine Recommendations for Americans

This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →